With concerns of biosimilar competition and revenue
erosion starting to fade, the market is giving more attention to the
strength of Roche’s (OTCQX:RHHBY)
portfolio of newer drugs and clinical pipeline, and the shares have
been outperforming. Although strong third-quarter results weren’t quite
as strong as they seem at first glance, it was nevertheless a good
beat-and-raise quarter and expectations for earnings growth over the
next three to five years have been improving.
Still a
major player in oncology, Roche has shown that it can successfully
broaden its horizons into other treatment areas like neurology. Roche
isn’t dramatically undervalued, but I still believe it is a worthwhile
buy-and-hold idea on the strength of its portfolio and pipeline.
Continue here:
Roche Delivers Accelerating Growth In The Third Quarter
No comments:
Post a Comment